MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at MOASC (Medical Oncology Association of Southern California), and the focus was on acute lymphoblastic leukemia, or ALL, along with any new updates on immunotherapy in this population.  Advertisement  Did anything stand out to you about … Continue reading MRD: 2023 ASH ALL Inotuzumab Update [Slides] – Van Huynh, MD MOASC